GlaxoSmithKline plc (GSK: Quote, GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.
Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.
Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org